PhRMA CEO Steve Ubl to Step Down by Year-End
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Steve Ubl is stepping down as CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) after more than a decade leading the brand drug industry's main trade group.
- Ubl plans to depart by the end of the year and will remain in his position until a new leader is found, according to a PhRMA statement.
- Ubl's tenure spanned the Covid-19 pandemic and aggressive political attacks on drug prices, with the source framing the period as 'tumultuous.'
- Democrats passed a law during Ubl's tenure directing Medicare to negotiate drug prices, a major policy shift for the industry PhRMA represents.
- The Trump administration struck voluntary deals with individual drugmakers aimed at lowering U.S. prices to levels in other high-income countries, adding a second front of pricing pressure on PhRMA members.
- PhRMA has not yet named a successor, leaving the timing of a leadership transition into a fundamentally reshaped drug-pricing policy landscape unsettled.
Why it matters: Ubl's exit lands as drug-pricing policy has been fundamentally reshaped on two fronts — the Medicare negotiation law and Trump-era most-favored-nation-style deals — meaning the next PhRMA CEO will inherit an industry whose pricing playbook has been rewritten mid-game, with no named successor yet announced.
